Pfizer Archives - Page 2 of 3 - CFO

Did Treasury Target Pfizer-Allergan Inversion?

Did Treasury Target Pfizer-Allergan Inversion?

The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.

By David Katz and Katie Kuehner-Hebert | April 6, 2016

Socially Responsible Companies Pay Lower Taxes

Socially Responsible Companies Pay Lower Taxes

A new study debunks the common notion that companies with high CSR ratings do not practice aggressive tax avoidance.

By David McCann | December 16, 2015

Clinton to Propose Crackdown on Inversions

Clinton to Propose Crackdown on Inversions

The presidential candidate would impose an "exit tax" on tax inversion deals that let U.S. firms reduce their taxes by merging with companies overseas.

By Matthew Heller | December 7, 2015

Finance Roundup for Executives

Corporate Finance

Finance Roundup for Executives

Be informed, get involved, and shape the world through finance. Here's today's CFO roundup.

By Kerry Maruna | November 24, 2015

Pfizer Buys Allergan for $160B

Pfizer Buys Allergan for $160B

The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.

By Katie Kuehner-Hebert | November 23, 2015

Strong Dollar Deflates Earnings

Management Accounting

Strong Dollar Deflates Earnings

Blue chips, including P&G, Dupont, and Pfizer, feel the effects of "unprecedented currency devaluations."

By Katie Kuehner-Hebert | January 27, 2015

Mergers and Acquisitions: Coming Unstuck

Mergers and Acquisitions: Coming Unstuck

When giant deals fail, life rarely goes back to normal.

By Economist Staff | August 11, 2014

Treasury Proposal Would Thwart Corporate Inversions

Treasury Proposal Would Thwart Corporate Inversions

In March the Treasury Department proposed an amendment to tax law, taking effect in 2015, that would prevent most corporate inversion transactions.

By Vincent Ryan | May 8, 2014

Divestitures Can Spawn Costly Human-Capital Errors

Divestitures Can Spawn Costly Human-Capital Errors

Amid a rush of spinoffs and carve-outs, parties to deals must watch out for people-related things they assume will work but won’t and important but often-overlooked considerations.

By David McCann | July 12, 2013

Financing Medical Research: Disease or Cure?

Financing Medical Research: Disease or Cure?

How securitisation may help your health.

By Economist Staff | January 25, 2013

The Prescription for Pharma Is Revenue Growth

The Prescription for Pharma Is Revenue Growth

Despite the hullabaloo about health-care reform, investors still reward revenue growth by pharmaceutical companies. But that growth requires organic and acquisitive reinvestment.

By Gregory V. Milano and John R. Cryan | April 4, 2012

Growth Strategies

Pfizer Defiant

How David Shedlarz challenges the analysts.

By Stephen Barr | July 1, 1999